Compare Adaptive Biotechnologies Corp (ADPT) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Cintas Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Cintas Corporation trades at $181.35 (market cap $72.76B). The key difference: Cintas Corporation is far larger — about 21.8× Adaptive Biotechnologies Corp's market cap, and Cintas Corporation pays a 0.99% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CTAS | |
|---|---|---|
Market Cap | $3.33B | $72.76B |
Sector | Health | Industrials |
52-Week High | $22.37 | $226.27 |
52-Week Low | $10.24 | $163.55 |
Enterprise Value | $3.19B | $75.49B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CTAS trades at $181.83, up 0.29% with a bullish technical signal. The stock shows strong fundamentals with revenue growing from $7.9B in 2022 to $10.3B in 2025 and net income margins expanding to 17.57%. Recent earnings mostly beat expectations, and the company maintains a 43-year dividend growth streak. Positive sentiment is supported by analyst coverage and recent corporate recognitions.
Outlook remains positive with a consensus price target of $212.50, implying 17% upside. Risks include elevated valuation multiples (P/E 37.6) and integration challenges from the UniFirst acquisition. The stock offers growth and income appeal but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
